138 related articles for article (PubMed ID: 10550740)
21. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
[TBL] [Abstract][Full Text] [Related]
22. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
23. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule.
Colás C; Monzón S; Venturini M; Lezaun A
J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938
[TBL] [Abstract][Full Text] [Related]
24. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever.
Ortolani C; Pastorello EA; Incorvaia C; Ispano M; Farioli L; Zara C; Pravettoni V; Zanussi C
Allergy; 1994 Jan; 49(1):13-21. PubMed ID: 8198235
[TBL] [Abstract][Full Text] [Related]
25. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial.
Ariano R; Kroon AM; Augeri G; Canonica GW; Passalacqua G
Allergy; 1999 Apr; 54(4):313-9. PubMed ID: 10371089
[TBL] [Abstract][Full Text] [Related]
26. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
Mäkelä MJ; Gyllfors P; Valovirta E; Steffensen MA; Grønager PM; Savolainen J; Winther L
Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
[TBL] [Abstract][Full Text] [Related]
28. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
29. Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation.
Passalacqua G; Albano M; Ruffoni S; Pronzato C; Riccio AM; Di Berardino L; Scordamaglia A; Canonica GW
Am J Respir Crit Care Med; 1995 Aug; 152(2):461-6. PubMed ID: 7633693
[TBL] [Abstract][Full Text] [Related]
30. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
[TBL] [Abstract][Full Text] [Related]
32. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy.
Calderon MA; Birk AO; Andersen JS; Durham SR
Allergy; 2007 Aug; 62(8):958-61. PubMed ID: 17620076
[TBL] [Abstract][Full Text] [Related]
33. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
34. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
35. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
Mösges R; Ritter B; Kayoko G; Allekotte S
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
[TBL] [Abstract][Full Text] [Related]
36. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
[TBL] [Abstract][Full Text] [Related]
37. Rush immunotherapy with sublingual administration of grass allergen extract.
Feliziani V; Marfisi RM; Parmiani S
Allergol Immunopathol (Madr); 1993; 21(5):173-8. PubMed ID: 8160561
[TBL] [Abstract][Full Text] [Related]
38. Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy.
Ventura MT; Carretta A; Tummolo RA; Buquicchio R; Arsieni A; Murgia N
Int J Immunopathol Pharmacol; 2009; 22(2):403-13. PubMed ID: 19505393
[TBL] [Abstract][Full Text] [Related]
39. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]